CLDI - Calidi Biotherapeutics, Inc.

0.3607
-0.409   -113.391%

Share volume: 4,164,395
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$0.77
-0.41
-0.53%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 35%
Liquidity 43%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-53.87%
1 Month
-56.31%
3 Months
-75.46%
6 Months
-78.14%
1 Year
-57.59%
2 Year
-48.03%
Key data
Stock price
$0.36
P/E Ratio 
0.00
DAY RANGE
$0.34 - $0.38
EPS 
-$3.99
52 WEEK RANGE
$0.20 - $7.25
52 WEEK CHANGE
-$54.36
MARKET CAP 
5.208 M
YIELD 
N/A
SHARES OUTSTANDING 
7.168 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$564,840
AVERAGE 30 VOLUME 
$264,960
Company detail
CEO: Allan J. Camaisa
Region: US
Website: www.calidibio.com
Employees: 38
IPO year: 2021
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company was founded in 2014 and is based in San Diego, California.

Recent news